Priority Research Papers:
Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner
Metrics: PDF 2109 views | HTML 6886 views | ?
Robin E. Frink1, Michael Peyton1, Joan H. Schiller2,4,8, Adi F. Gazdar1,3,4, Jerry W. Shay4,5,6 and John D. Minna1,4,7,8
1 Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 Inova Schar Cancer Institute, Falls Church, VA, USA
3 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
4 Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
5 Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA
6 Center for Excellence in Genomics Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
7 Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA
8 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
John D. Minna, e-mail:
Keywords: imetelstat, telomerase, telomeres, lung cancer, telomerase inhibition
Received: December 04, 2015 Accepted: April 27, 2016 Published: May 12, 2016
Telomerase was evaluated as a therapeutic oncotarget by studying the efficacy of the telomerase inhibitor imetelstat in non-small cell lung cancer (NSCLC) cell lines to determine the range of response phenotypes and identify potential biomarkers of response. A panel of 63 NSCLC cell lines was studied for telomere length and imetelstat efficacy in inhibiting colony formation and no correlation was found with patient characteristics, tumor histology, and oncogenotypes. While there was no overall correlation between imetelstat efficacy with initial telomere length (ranging from 1.5 to 20 kb), the quartile of NSCLC lines with the shortest telomeres was more sensitive than the quartile with the longest telomeres. Continuous long-term treatment with imetelstat resulted in sustained telomerase inhibition, progressive telomere shortening and eventual growth inhibition in a telomere-length dependent manner. Cessation of imetelstat therapy before growth inhibition was followed by telomere regrowth. Likewise, in vivo imetelstat treatment caused tumor xenograft growth inhibition in a telomere-length dependent manner. We conclude from these preclinical studies of telomerase as an oncotarget tested by imetelstat response that imetelstat has efficacy across the entire oncogenotype spectrum of NSCLC, continuous therapy is necessary to prevent telomere regrowth, and short telomeres appears to be the best treatment biomarker.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.